Developer docs
API playgroundTry for free, no card

Search company profiles

Frazier Life Sciences

Full company profile

uuid0000u9i

Namestring
Frazier Life Sciences
Legal namestring
Frazier Life Sciences Management, L.P.
Websiteurl
frazierls.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Frazier Life Sciences (legal entity: Frazier Life Sciences Management, L.P.) is a privately held, Palo Alto–headquartered biotech investment firm operating two integrated strategies under one roof: a venture capital strategy focused on early-stage private biopharmaceutical companies (>$4B AUM as of December 31, 2025) and a long-only, evergreen public equity strategy focused on small and mid-cap public biopharmaceuticals and crossover rounds (>$2.8B AUM as of December 31, 2025). Across both strategies the firm manages more than $5B in assets, drawing capital from institutional Limited Partners.

The firm’s core activity is company creation and structured private investment across therapeutic areas (oncology, autoimmune, CNS, ophthalmology, vaccines, orphan diseases, respiratory, cardiometabolic) and modalities (small molecules, biologics, ADCs, gene therapy, cell therapy, radiopharmaceuticals). Its venture team has created 25+ companies since 2015 via spin-outs and de novo formation — examples include Radionetics Oncology (co-created with 5AM Ventures and Crinetics in 2021), Attovia Therapeutics (launched with Alamar Biosciences in 2023), AirNexis Therapeutics (2026 launch with $200M Series A), and GondolaBio (with BridgeBio). The firm also participates in Series A/B/C rounds, often as lead investor, and supports IPOs and de-SPAC transitions (e.g., the Frazier Lifesciences Acquisition Company/FLAC that merged with NewAmsterdam Pharma in 2022 to create NASDAQ: NAMS). Portfolio exits include Alpine Immune Sciences (acquired by Vertex for $4.9B in 2024) and Krystal Biotech (public market support since IPO). The cross-fund venture/public architecture enables continued PIPE and ATM financing of portfolio companies post-IPO, supported by a 15+ person investment team of MDs/PhDs led by Managing Partner Albert Cha.

The firm earns revenue through two primary streams: (i) recurring management fees on committed and invested fund capital from Limited Partners — fee rates are not publicly disclosed — and (ii) carried interest/performance fees on successful exits, which are episodic and tied to realized gains across the venture and public portfolios. The firm has offices in Palo Alto (headquarters), San Diego, Boston, and Seattle (opened February 2026), and is privately held with no parent company or public listing.

Short descriptiontext

Frazier Life Sciences is a privately held biotech investment firm managing more than $5B across integrated venture and public equity strategies, partnering with and building companies developing novel therapeutics from seed through IPO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotech venture capital, life sciences investing, biopharmaceutical investments, company creation, public equity strategy
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Investment Advice6282
Product category
Biotech Investment Management
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Management Fees
TypeSubscription Recurring
Description

Frazier Life Sciences earns management fees from investors (Limited Partners) in its venture and public equity funds. The firm manages over $4B in venture capital AUM and over $2.8B in public equity AUM (as of December 31, 2025).

2Carried Interest / Performance Fees
TypeSubscription Recurring
Description

As a venture capital and public equity firm, FLS earns carried interest and/or performance fees on successful investments. The firm's venture strategy generated over $75B in cumulative IPO/M&A transaction value since 2015, providing upside on successful exits.

3Venture Fund Capital Raises
TypeLicensing Royalties
Description

FLS closed an oversubscribed $1.3 billion venture fund in July 2025, representing the firm's primary vehicle for deploying capital into early-stage private biopharmaceutical companies through company creation and Series A/B/C investments.

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Frazier Life Sciences is a private biotech investment firm that manages dedicated venture capital and public equity strategies focused on biopharmaceutical companies. The venture strategy creates and builds early-stage private companies and leads Series A/B/C financings, while the public equity strategy invests in small and mid-cap public biopharmaceutical companies and crossover rounds. The firm manages more than $5 billion in combined assets under management across both strategies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Frazier Life Sciences (FLS) is a longstanding biotech investment firm rather than a traditional software product company. Its offering is a platform-plus-strategies architecture composed of two core strategies: the Venture Capital Strategy (over $4B AUM, focused on early-stage private biopharmaceutical companies, company creation, and Series A investments) and the Public Equity Strategy (over $2.8B AUM, focused on small and mid-cap public biopharmas and crossover rounds). These strategies are complemented by the Frazier Life Sciences Acquisition Company (FLAC), a former Frazier-sponsored SPAC that merged with NewAmsterdam Pharma in 2022 to create NewAmsterdam Pharma (NASDAQ: NAMS). The portfolio spans a wide range of therapeutic areas (oncology, autoimmune, CNS, vaccines, ophthalmology, orphan diseases, etc.) and modalities (small molecules, biologics, ADCs, cell therapy, gene therapy, radiopharmaceuticals) across dozens of named portfolio companies such as Krystal Biotech, Alpine Immune Sciences, Arcutis Biotherapeutics, Halda Therapeutics, and BridgeBio.

Product and service2 records
1Frazier Life Sciences Venture Capital Strategy
CategoryInvestment Strategy
2Frazier Life Sciences Public Equity Strategy
CategoryInvestment Strategy
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-dedicated investment firm spanning venture, growth, and public equity strategies. Comparable to FLS's integrated venture-and-public approach, though with significantly larger AUM.

TypeDirect peer
Description

Early-stage biotech venture firm that builds companies around novel science, comparable in size and strategy to Frazier's venture arm. Both employ a company-creation model and operate from major US biotech hubs.

3Baker Bros. Advisors
TypeDirect peer
Description

Biotech-focused long-only advisor investing across public and private companies. Comparable to Frazier's integrated public/venture model with deep sector specialization.

TypeDirect peer
Description

One of the largest US biotech-focused venture firms, originating and co-creating companies across modalities and stages. Comparable to FLS in company-creation approach and life-sciences specialization, with a broader AUM base.

TypeDirect peer
Description

Biotech-focused early-stage venture capital firm that co-led Radionetics Oncology with Frazier Life Sciences. Directly comparable as a co-creation partner in company formation, with similar AUM scale and a focus on translational science.

TypeBroad incumbent
Description

Large diversified venture firm with a dedicated healthcare practice that invests across biotech stages. Comparable in venture stage focus but operates a much broader multi-sector platform than FLS's life-sciences-only mandate.

TypeDirect peer
Description

Crossover healthcare investor operating public and private strategies, frequently co-investing in Series A rounds alongside FLS. Similar domain specialization and stage coverage makes it a direct competitor for biotech mandates.

TypeEmerging player
Description

Biotech-focused venture firm investing in therapeutic platforms with company-creation elements. Comparable strategic approach but typically at smaller check sizes and lower AUM than FLS.

TypeDirect peer
Description

Healthcare-dedicated venture firm with a comparable company-creation approach (e.g., Inception Therapeutics). Similar AUM scale and stage focus to FLS, making it a close peer for LP benchmarking and deal co-investment.

TypeBroad incumbent
Description

Healthcare-dedicated investment manager with venture, public, and private credit strategies. Comparable domain focus but materially larger and more diversified than Frazier's pure-play biotech platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment20 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frazier Life Sciences

Biotech Investment Managementfrazierls.com

Frazier Life Sciences is a privately held biotech investment firm managing more than $5B across integrated venture and public equity strategies, partnering with and building companies developing novel therapeutics from seed through IPO.

What Frazier Life Sciences does

Frazier Life Sciences (legal entity: Frazier Life Sciences Management, L.P.) is a privately held, Palo Alto–headquartered biotech investment firm operating two integrated strategies under one roof: a venture capital strategy focused on early-stage private biopharmaceutical companies (>$4B AUM as of December 31, 2025) and a long-only, evergreen public equity strategy focused on small and mid-cap public biopharmaceuticals and crossover rounds (>$2.8B AUM as of December 31, 2025). Across both strategies the firm manages more than $5B in assets, drawing capital from institutional Limited Partners.

The firm’s core activity is company creation and structured private investment across therapeutic areas (oncology, autoimmune, CNS, ophthalmology, vaccines, orphan diseases, respiratory, cardiometabolic) and modalities (small molecules, biologics, ADCs, gene therapy, cell therapy, radiopharmaceuticals). Its venture team has created 25+ companies since 2015 via spin-outs and de novo formation — examples include Radionetics Oncology (co-created with 5AM Ventures and Crinetics in 2021), Attovia Therapeutics (launched with Alamar Biosciences in 2023), AirNexis Therapeutics (2026 launch with $200M Series A), and GondolaBio (with BridgeBio). The firm also participates in Series A/B/C rounds, often as lead investor, and supports IPOs and de-SPAC transitions (e.g., the Frazier Lifesciences Acquisition Company/FLAC that merged with NewAmsterdam Pharma in 2022 to create NASDAQ: NAMS). Portfolio exits include Alpine Immune Sciences (acquired by Vertex for $4.9B in 2024) and Krystal Biotech (public market support since IPO). The cross-fund venture/public architecture enables continued PIPE and ATM financing of portfolio companies post-IPO, supported by a 15+ person investment team of MDs/PhDs led by Managing Partner Albert Cha.

The firm earns revenue through two primary streams: (i) recurring management fees on committed and invested fund capital from Limited Partners — fee rates are not publicly disclosed — and (ii) carried interest/performance fees on successful exits, which are episodic and tied to realized gains across the venture and public portfolios. The firm has offices in Palo Alto (headquarters), San Diego, Boston, and Seattle (opened February 2026), and is privately held with no parent company or public listing.

Frazier Life Sciences firmographics

Firmographics
Name
Frazier Life Sciences
Legal name
Frazier Life Sciences Management, L.P.
Website
https://frazierls.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Frazier Life Sciences is a privately held biotech investment firm managing more than $5B across integrated venture and public equity strategies, partnering with and building companies developing novel therapeutics from seed through IPO.
Ownership category
akta.pro rank

Frazier Life Sciences industry classification

Industry
Product category
Biotech Investment Management
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Biotech venture capital
  • Life sciences investing
  • Biopharmaceutical investments
  • Company creation
  • Public equity strategy

Where Frazier Life Sciences is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Markets served

Frazier Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Management Fees: Frazier Life Sciences earns management fees from investors (Limited Partners) in its venture and public equity funds. The firm manages over $4B in venture capital AUM and over $2.8B in public equity AUM (as of December 31, 2025).
  2. Carried Interest / Performance Fees: As a venture capital and public equity firm, FLS earns carried interest and/or performance fees on successful investments. The firm's venture strategy generated over $75B in cumulative IPO/M&A transaction value since 2015, providing upside on successful exits.
  3. Venture Fund Capital Raises: FLS closed an oversubscribed $1.3 billion venture fund in July 2025, representing the firm's primary vehicle for deploying capital into early-stage private biopharmaceutical companies through company creation and Series A/B/C investments.

Go-to-market motion3 records

Frazier Life Sciences product offering

Product offering

Core offering

Frazier Life Sciences is a private biotech investment firm that manages dedicated venture capital and public equity strategies focused on biopharmaceutical companies. The venture strategy creates and builds early-stage private companies and leads Series A/B/C financings, while the public equity strategy invests in small and mid-cap public biopharmaceutical companies and crossover rounds. The firm manages more than $5 billion in combined assets under management across both strategies.

Product overview

Frazier Life Sciences (FLS) is a longstanding biotech investment firm rather than a traditional software product company. Its offering is a platform-plus-strategies architecture composed of two core strategies: the Venture Capital Strategy (over $4B AUM, focused on early-stage private biopharmaceutical companies, company creation, and Series A investments) and the Public Equity Strategy (over $2.8B AUM, focused on small and mid-cap public biopharmas and crossover rounds). These strategies are complemented by the Frazier Life Sciences Acquisition Company (FLAC), a former Frazier-sponsored SPAC that merged with NewAmsterdam Pharma in 2022 to create NewAmsterdam Pharma (NASDAQ: NAMS). The portfolio spans a wide range of therapeutic areas (oncology, autoimmune, CNS, vaccines, ophthalmology, orphan diseases, etc.) and modalities (small molecules, biologics, ADCs, cell therapy, gene therapy, radiopharmaceuticals) across dozens of named portfolio companies such as Krystal Biotech, Alpine Immune Sciences, Arcutis Biotherapeutics, Halda Therapeutics, and BridgeBio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Frazier Life Sciences Venture Capital Strategy
  • Frazier Life Sciences Public Equity Strategy

Companies that use Frazier Life Sciences

Customer profile

Ideal customer profiles2 records

Frazier Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Frazier Life Sciences partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights5 records

Frazier Life Sciences competitors and assessment

Company assessment

Direct peers

  • OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and public equity strategies. Comparable to FLS's integrated venture-and-public approach, though with significantly larger AUM.
  • Atlas Venture: Early-stage biotech venture firm that builds companies around novel science, comparable in size and strategy to Frazier's venture arm. Both employ a company-creation model and operate from major US biotech hubs.
  • Baker Bros. Advisors: Biotech-focused long-only advisor investing across public and private companies. Comparable to Frazier's integrated public/venture model with deep sector specialization.
  • ARCH Venture Partners: One of the largest US biotech-focused venture firms, originating and co-creating companies across modalities and stages. Comparable to FLS in company-creation approach and life-sciences specialization, with a broader AUM base.
  • 5AM Ventures: Biotech-focused early-stage venture capital firm that co-led Radionetics Oncology with Frazier Life Sciences. Directly comparable as a co-creation partner in company formation, with similar AUM scale and a focus on translational science.
  • RA Capital Management: Crossover healthcare investor operating public and private strategies, frequently co-investing in Series A rounds alongside FLS. Similar domain specialization and stage coverage makes it a direct competitor for biotech mandates.
  • Versant Ventures: Healthcare-dedicated venture firm with a comparable company-creation approach (e.g., Inception Therapeutics). Similar AUM scale and stage focus to FLS, making it a close peer for LP benchmarking and deal co-investment.

Broad incumbents

  • New Enterprise Associates (NEA): Large diversified venture firm with a dedicated healthcare practice that invests across biotech stages. Comparable in venture stage focus but operates a much broader multi-sector platform than FLS's life-sciences-only mandate.
  • Deerfield Management: Healthcare-dedicated investment manager with venture, public, and private credit strategies. Comparable domain focus but materially larger and more diversified than Frazier's pure-play biotech platform.

Emerging players

  • venBio Partners: Biotech-focused venture firm investing in therapeutic platforms with company-creation elements. Comparable strategic approach but typically at smaller check sizes and lower AUM than FLS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Frazier Life Sciences social profiles

Digital presence

Frazier Life Sciences compliance and trust

Trust signal

Compliance3 records

Frazier Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Frazier Life Sciences leadership team

Management profile

Number of profiles

Profiles10 records

Frazier Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Frazier Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Frazier Life Sciences M&A and investment

M&A and investment

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frazier Life Sciences

What does Frazier Life Sciences do?

Frazier Life Sciences is a private biotech investment firm that manages dedicated venture capital and public equity strategies focused on biopharmaceutical companies. The venture strategy creates and builds early-stage private companies and leads Series A/B/C financings, while the public equity strategy invests in small and mid-cap public biopharmaceutical companies and crossover rounds. The firm manages more than $5 billion in combined assets under management across both strategies.

Is Frazier Life Sciences a public or private company?

Frazier Life Sciences is a private company. It is classified as management employee owned and is currently operating.

When was Frazier Life Sciences founded?

Frazier Life Sciences was founded in 2015. It employs 51 to 100 people.

Where is Frazier Life Sciences based?

Frazier Life Sciences is headquartered in Palo Alto, United States, in the North America region.

How does Frazier Life Sciences make money?

Three revenue lines are on record. Management Fees are the primary driver. The others are carried Interest / Performance Fees and venture Fund Capital Raises.

Who are Frazier Life Sciences's main competitors?

Direct peers on record are OrbiMed, Atlas Venture, Baker Bros. Advisors, ARCH Venture Partners, 5AM Ventures, RA Capital Management and Versant Ventures. Broad incumbents are New Enterprise Associates (NEA) and Deerfield Management. venBio Partners is listed as an emerging player.

Does Frazier Life Sciences have an API?

No public API is recorded for Frazier Life Sciences.

What industry is Frazier Life Sciences in?

Frazier Life Sciences's product category is Biotech Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 541714 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coRezolute prices $100M stock offering led by Frazier Life Sciences | Dealroom NewsRezolute priced a $100M stock offering led by Frazier Life Sciences, with Morgan Stanley and Guggenheim as book-runners. The financing closes around November 16, 2026, and coincides with its Phase 3 upLIFT study meeting its primary efficacy endpoint. Proceeds will fund commercialization preparation for ersodetug, with a BLA submission targeted for mid-2027.The future of tradingRezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsRezolute priced an underwritten offering of 22,040,976 common shares at $3.87 each and pre-funded warrants, with gross proceeds of approximately $100 million. The offering is led by Frazier Life Sciences and is expected to close on November 16, 2026. Proceeds will fund commercialization preparation, working capital, and general corporate purposes.FinancialContent Business PageRezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsRezolute priced an underwritten offering of 22,040,976 common shares at $3.87 each and pre-funded warrants, with gross proceeds expected near $100 million. The offering, led by Frazier Life Sciences, is expected to close on November 16, 2026. Proceeds will fund commercialization preparation, working capital, and general corporate purposes.GlobeNewswireRezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsRezolute priced an underwritten offering of 22,040,976 common shares at $3.87 each and pre-funded warrants, with gross proceeds expected near $100 million. The offering, led by Frazier Life Sciences, is expected to close on November 16, 2026. Proceeds will fund commercialization preparation, working capital, and general corporate purposes.Stock TitanRezolute prices stock offering with ~$100M gross proceedsRezolute priced an underwritten offering of 22,040,976 common shares at $3.87 each and pre-funded warrants, with gross proceeds expected near $100 million. The offering, led by Frazier Life Sciences, is expected to close on November 16, 2026. Proceeds will fund commercialization preparation, working capital, and general corporate purposes.TradingViewRezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsRezolute priced an underwritten offering of 22,040,976 common shares at $3.87 each and pre-funded warrants, with gross proceeds expected near $100 million. The offering, led by Frazier Life Sciences, is expected to close on November 16, 2026. Proceeds will fund commercialization preparation, working capital, and general corporate purposes.LelezardAnaheim Bio lève 40 millions d'euros en série A pour faire avancer l'ANA-1, un traitement contre la maladie de dépôt de pyrophosphate de calcium, jusqu'aux essais cliniquesAnaheim Bio raised a €40 million Series A to advance ANA-1, a small-molecule treatment for calcium pyrophosphate deposition disease (CPPD), into clinical trials. The company expects to enter phase 1 in 2027, with cash reserves through 2028. The funding comes from investors including Droia Ventures and Frazier Life Sciences.FinSMEsAnaheim Bio Raises €40M in Series A FundingAnaheim Bio raised €40M in Series A funding from backers including Droia Ventures, Frazier Life Sciences, and Novartis Venture Fund. The company will use the funds to advance ANA-1, a small molecule for calcium pyrophosphate deposition disease, through IND-enabling studies and into Phase 1.BitlyAnaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the ClinicAnaheim Bio, spun out of Alesta Therapeutics, raised €40 million in Series A financing to advance ANA-1, a small molecule for calcium pyrophosphate deposition disease. The company expects clinic entry in 2027, with the financing supporting IND-enabling studies and Phase 1. The lead investors include Droia Ventures, Frazier Life Sciences, and Novartis Venture Fund.Pulse 2.0Frazier Life Sciences Raises More Than $1.1 Billion For Public Biotech Fund, Bringing Commitments To $2.8 BillionFrazier Life Sciences raised over $1.1 billion in new commitments for its public biotech fund, bringing total committed capital to about $2.8 billion. The fund targets small- and mid-cap public biotech companies, with Verona Pharma and Alpine Immune Sciences among its largest historical holdings.